LU91269I2 - Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro) - Google Patents

Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)

Info

Publication number
LU91269I2
LU91269I2 LU91269C LU91269C LU91269I2 LU 91269 I2 LU91269 I2 LU 91269I2 LU 91269 C LU91269 C LU 91269C LU 91269 C LU91269 C LU 91269C LU 91269 I2 LU91269 I2 LU 91269I2
Authority
LU
Luxembourg
Prior art keywords
neupro
rotigotine
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU91269C
Other languages
English (en)
Other versions
LU91269I9 (fr
Original Assignee
Schwarz Pharma Ltd
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7862904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91269(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma Ltd, Lohmann Therapie Syst Lts filed Critical Schwarz Pharma Ltd
Publication of LU91269I2 publication Critical patent/LU91269I2/fr
Publication of LU91269I9 publication Critical patent/LU91269I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU91269C 1998-03-30 2006-07-26 Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro) LU91269I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814084A DE19814084B4 (de) 1998-03-30 1998-03-30 D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
PCT/EP1999/001795 WO1999049852A1 (fr) 1998-03-30 1999-03-18 Systeme therapeutique transdermique contenant un agoniste d2 servant a traiter le syndrome parkinsonien, et son procede de production

Publications (2)

Publication Number Publication Date
LU91269I2 true LU91269I2 (fr) 2006-09-26
LU91269I9 LU91269I9 (fr) 2018-12-31

Family

ID=7862904

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91269C LU91269I2 (fr) 1998-03-30 2006-07-26 Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)

Country Status (30)

Country Link
US (4) US6884434B1 (fr)
EP (1) EP1033978B1 (fr)
JP (1) JP3984785B2 (fr)
KR (1) KR100432276B1 (fr)
CN (1) CN1142773C (fr)
AR (1) AR014778A1 (fr)
AT (1) ATE210973T1 (fr)
AU (1) AU746856B2 (fr)
BR (1) BRPI9909313B8 (fr)
CA (1) CA2326630C (fr)
CZ (1) CZ297889B6 (fr)
DE (4) DE19814084B4 (fr)
DK (1) DK1033978T3 (fr)
ES (1) ES2170573T3 (fr)
FR (1) FR06C0025I2 (fr)
HU (1) HU226733B1 (fr)
ID (1) ID26646A (fr)
IL (1) IL138722A (fr)
LU (1) LU91269I2 (fr)
MY (1) MY119660A (fr)
NL (1) NL300236I2 (fr)
NO (3) NO325766B1 (fr)
NZ (1) NZ507066A (fr)
PL (1) PL193074B1 (fr)
PT (1) PT1033978E (fr)
SK (1) SK284618B6 (fr)
TR (1) TR200002829T2 (fr)
TW (1) TW579299B (fr)
WO (1) WO1999049852A1 (fr)
ZA (1) ZA200005261B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19918106A1 (de) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
CA2374930C (fr) 1999-07-02 2008-08-05 Lts Lohmann Therapie-Systeme Ag Systeme a microreservoir a base de polysiloxanes et de solvants ambiphiliques
DE10054713C2 (de) * 1999-11-29 2002-07-18 Lohmann Therapie Syst Lts Transdermale Therapeutische Systeme mit verbesserter Stabilität und ein Verfahren zu ihrer Herstellung
WO2001039753A1 (fr) * 1999-11-29 2001-06-07 Lts Lohmann Therapie-Systeme Ag Systemes therapeutiques transdermiques ayant une stabilite amelioree et procede de fabrication
DE10012908B4 (de) * 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU2005242160B2 (en) * 2000-10-12 2009-02-26 Lts Lohmann Therapie-Systeme Ag Improved transdermal therapeutic system for the treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
ATE246919T1 (de) * 2001-05-08 2003-08-15 Sanol Arznei Schwarz Gmbh Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
EP1256339B1 (fr) * 2001-05-08 2003-10-15 Schwarz Pharma Ag Système thérapeutique transdermique pour l'obtention de taux plasmatiques élevés de rotigotine dans le traitement de morbus Parkinson
DE10137082A1 (de) 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10159745A1 (de) 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
EP1386605A1 (fr) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Systeme transdermique ameliore pour l'administration de rotigotin
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1386604A1 (fr) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Systeme d'administation transdermique amélioré
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
NZ541576A (en) * 2003-02-07 2008-03-28 Lohmann Therapie Syst Lts Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (fr) 2003-12-23 2005-06-29 Schwarz Pharma Ag Formulation intranasale contenant
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP2008514376A (ja) * 2004-09-29 2008-05-08 シュウォーツ ファーマ インコーポレイテッド パーキンソン病のための経皮治療システム
CA2548864C (fr) 2005-06-06 2012-12-11 Nitto Denko Corporation Preparation pharmaceutique a administrer par voie cutanee
JP5025998B2 (ja) * 2005-06-06 2012-09-12 日東電工株式会社 経皮吸収製剤
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
DE102006028987A1 (de) 2006-06-24 2007-12-27 Lts Lohmann Therapie-Systeme Ag Ultraschallverstärktes transdermales therapeutisches System
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
EP1987815A1 (fr) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Compositions pharmaceutiques à base d'agonistes dopaminergiques administrables par voie oro-naso-pharyngale pour la prévention et/ou le traitement de membres sans repos
CN101147739B (zh) * 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
WO2009063171A1 (fr) * 2007-11-16 2009-05-22 Pliva Hrvatska D.O.O. Nouveaux sels de rotigotine
RS54235B1 (sr) * 2007-11-28 2015-12-31 Ucb Pharma Gmbh Polimorfni oblik rotigotina
JP5546013B2 (ja) 2008-02-27 2014-07-09 久光製薬株式会社 貼付剤及び包装体
JP5537412B2 (ja) * 2008-02-27 2014-07-02 久光製薬株式会社 貼付製剤
DE102008013701A1 (de) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit stabilisierter Membran
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
WO2009139213A1 (fr) * 2008-05-15 2009-11-19 日本臓器製薬株式会社 Composition pharmaceutique pour application externe contenant de la prochlorpérazine
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (fr) * 2008-12-29 2010-06-30 UCB Pharma GmbH Technologie de fabrication de pavé
DE102009022915A1 (de) * 2009-05-27 2010-12-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit gesteuertem Wirkstofffluss
EP2281559A1 (fr) 2009-06-26 2011-02-09 UCB Pharma GmbH Composition pharmaceutique contenante un sel de rotigotine (sel d'acid ou Na), notament pour iontophorèse
EP2490673A2 (fr) * 2009-10-19 2012-08-29 Actavis Group Ptc Ehf Co-précipités de rotigotine amorphes
EP2338873A1 (fr) 2009-12-22 2011-06-29 Gmeiner, Peter Nouveaux dérivés d'aminotétraline
HRP20181173T1 (hr) 2009-12-22 2018-09-21 Ucb Biopharma Sprl Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina
EP2457565A1 (fr) 2010-11-29 2012-05-30 Ratiopharm GmbH Système thérapeutique transdermique comportant de la rotigotine
EP2646009A1 (fr) 2010-12-02 2013-10-09 Ratiopharm GmbH Liquide ionique de rotigotine
WO2012084969A1 (fr) 2010-12-22 2012-06-28 Hexal Ag Composition adhésive contenant de la rotigotine et système thérapeutique transdermique comprenant la composition adhésive
WO2013020527A1 (fr) 2011-08-11 2013-02-14 University Of Veterinary And Pharmaceutical Sciences Brno Faculty Of Pharmacy Utilisation d'alaptide en tant que modificateur de pénétration transdermique dans des compositions pharmaceutiques pour des applications humaines et vétérinaires contenant des médicaments anti-inflammatoires et/ou des agents chimiothérapeutiques antimicrobiens
EP2559435A1 (fr) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine pour le traitement des négligences spatiales unilatérales, accidents vasculaires cérébraux et troubles suivant un accident vasculaire
CN102499906B (zh) * 2011-10-12 2013-04-17 长春健欣生物医药科技开发有限公司 一种罗替戈汀盐酸盐或自由碱成膜凝胶制剂及其制备方法
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
WO2013075822A1 (fr) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Système thérapeutique transdermique (tts) comportant de la rotigotine
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
DE102012205493A1 (de) * 2012-04-03 2013-10-10 Acino Ag Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
CA2878376C (fr) 2012-07-05 2018-08-07 Sk Chemicals Co., Ltd. Preparation absorbable par voie transdermique contenant de la rotigotine
KR101558043B1 (ko) * 2012-07-06 2015-10-07 에스케이케미칼주식회사 로티고틴 함유 경피흡수제제
TW201431570A (zh) * 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2014198422A1 (fr) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Système thérapeutique transdermique (tts) doté de rotigotine
CA2916183C (fr) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique dote d'un composant electronique
EP4238580A3 (fr) 2014-05-20 2023-10-25 LTS Lohmann Therapie-Systeme AG Systeme d'administration transdermique comprenant un mediateur d'interface
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
JP6895755B2 (ja) 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
US10011629B2 (en) 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
CN109806243B (zh) * 2017-11-20 2022-07-15 北京泰德制药股份有限公司 一种含有氟吡汀或其药用盐的皮肤外用贴剂
US11607394B2 (en) 2017-12-19 2023-03-21 Hisamitsu Pharmaceutical Co., Inc. Rotigotine-containing patch
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺
EP3584244A1 (fr) 2018-06-20 2019-12-25 UCB Pharma GmbH Indolsulfonamides alkoxypyridinyl substitués
KR102731700B1 (ko) 2018-10-24 2024-11-15 에스케이케미칼 주식회사 비결정 로티고틴 함유 조성물 및 이의 제조 방법
US20220117934A1 (en) 2019-02-15 2022-04-21 Hisamitsu Pharmaceutical Co., Inc. Rotigotine stabilization method
MX2021014742A (es) 2019-06-05 2022-02-11 Univ Emory Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
US20220257528A1 (en) 2019-06-14 2022-08-18 Hisamitsu Pharmaceutical Co., Inc. Rotigotine-containing patch
CN113993845A (zh) 2019-06-17 2022-01-28 优时比制药有限公司 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物
PL3854388T3 (pl) 2020-01-24 2024-02-26 Luye Pharma Switzerland Ag Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin
CN113368083A (zh) * 2021-06-16 2021-09-10 华健医疗(深圳)有限公司 一种大麻二酚cbd透皮给药系统
WO2023157865A1 (fr) 2022-02-21 2023-08-24 久光製薬株式会社 Timbre adhésif contenant de la rotigotine
EP4483873A4 (fr) 2022-02-21 2026-02-18 Hisamitsu Pharmaceutical Co Timbre adhésif contenant de la rotigotine
EP4628076A1 (fr) 2022-12-01 2025-10-08 Hisamitsu Pharmaceutical Co., Inc. Timbre contenant de la rotigotine et procédé pour améliorer la stabilité de la rotigotine
WO2024144130A1 (fr) 2022-12-26 2024-07-04 환인제약 주식회사 Formulation pour absorption transdermique et son procédé de préparation

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268385A (en) 1983-01-03 1993-12-07 Whitby Research, Inc. Method for treating schizophrenia
US5177112A (en) * 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5273757A (en) * 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems
DE3827561C1 (fr) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
EP0387751B1 (fr) * 1989-03-15 1994-06-08 Nitto Denko Corporation Pansement contenant un médicament
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2648131B1 (fr) * 1989-06-13 1991-10-18 Oreal Nouveaux derives de tetrahydro -5,6,7,8 naphtalenol-1, leur procede de preparation et leur utilisation en tant qu'agents antioxydants dans des compositions cosmetiques et pharmaceutiques les contenant
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) * 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
US5246997A (en) * 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5147916A (en) * 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
US5273756A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5234690A (en) * 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5273755A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
JPH06510290A (ja) * 1991-08-27 1994-11-17 シグナス，インコーポレイテッド プラゾシンを投与するための経皮処方物
AU2782592A (en) 1991-10-15 1993-05-21 Cygnus Therapeutic Systems Thermal enhancement of transdermal drug administration
WO1993014727A1 (fr) 1992-01-31 1993-08-05 Cygnus Therapeutic Systems Administration transcutanee de buprenorphine sous forme de complexes de paires d'ion
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
AU3247193A (en) 1992-08-25 1994-03-15 Cygnus Therapeutic Systems Printed transdermal drug delivery device
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
DE4301781C2 (de) * 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
JPH09501909A (ja) 1993-06-24 1997-02-25 シグナス セラピューティク システムズ 経皮送達システムパッケージ
US5804214A (en) 1993-07-08 1998-09-08 Cygnus, Inc. Monolithic matrix transdermal delivery system for delivering ketorolac tromethamine
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
AU7517794A (en) 1993-08-16 1995-03-14 Cygnus Therapeutic Systems Transdermal delivery system using a combination of permeation enhancers
AU7566994A (en) 1993-08-16 1995-03-14 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
DE69527408T2 (de) 1994-03-11 2003-02-20 Koninklijke Philips Electronics N.V., Eindhoven Übertragungssystem für quasiperiodische signale
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
DK0766578T3 (da) 1994-06-24 2000-10-23 Cygnus Therapeutic Systems Iontophoretisk prøvetagningsindretning
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
AU4657896A (en) 1995-01-19 1996-08-07 Cygnus, Inc. Polyisobutylene adhesives containing high TG tackifier for transdermal devices
AU4761196A (en) 1995-01-19 1996-08-07 Cygnus, Inc. Polymer adhesive formulation containing sorbent particles
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
US6316022B1 (en) * 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DK0836506T4 (da) * 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
AU7238896A (en) 1995-09-14 1997-04-01 Cygnus, Inc. High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US6063398A (en) * 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5879701A (en) * 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
US5843472A (en) * 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE69902229T2 (de) * 1998-05-13 2003-02-20 Cygnus, Inc. Sammelvorrichtungen für transdermale probennahmesysteme
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE69913153D1 (de) * 1998-09-17 2004-01-08 Cygnus Therapeutic Systems Gerät zum zusammendrücken einer gel/sensor-einheit
FR2792529B1 (fr) 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
US6465004B1 (en) * 1999-06-05 2002-10-15 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
KR100317533B1 (ko) * 1999-11-10 2001-12-24 윤종용 반도체 집적회로 장치에서의 레이저 퓨즈박스의 구조 및그에 따른 제조 방법
HK1052514A1 (zh) * 1999-11-23 2003-09-19 阿德里斯制药公司 制备氮取代的氨基1，2，3，4-四氢化萘的改进方法
WO2001039753A1 (fr) * 1999-11-29 2001-06-07 Lts Lohmann Therapie-Systeme Ag Systemes therapeutiques transdermiques ayant une stabilite amelioree et procede de fabrication
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
DE10018467A1 (de) 2000-04-14 2001-10-25 Bosch Gmbh Robert Elektrische Maschine
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
FR2829028B1 (fr) * 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
AU2003223579A1 (en) * 2002-04-18 2003-11-03 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US20060216336A1 (en) 2002-05-07 2006-09-28 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
JP5160018B2 (ja) * 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
US7379762B2 (en) 2003-09-04 2008-05-27 Creative Technology Ltd. Portable digital device orientation
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (fr) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Formulation intranasale contenant
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (fr) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Compositions pharmaceutiques à base d'agonistes dopaminergiques administrables par voie oro-naso-pharyngale pour la prévention et/ou le traitement de membres sans repos
RS54235B1 (sr) 2007-11-28 2015-12-31 Ucb Pharma Gmbh Polimorfni oblik rotigotina
EP2281559A1 (fr) 2009-06-26 2011-02-09 UCB Pharma GmbH Composition pharmaceutique contenante un sel de rotigotine (sel d'acid ou Na), notament pour iontophorèse
HRP20181173T1 (hr) 2009-12-22 2018-09-21 Ucb Biopharma Sprl Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina

Also Published As

Publication number Publication date
HUP0101519A3 (en) 2002-10-28
NO2008014I1 (no) 2008-11-03
CA2326630A1 (fr) 1999-10-07
NL300236I2 (nl) 2006-12-01
NL300236I1 (nl) 2006-10-02
BR9909313A (pt) 2000-11-21
NZ507066A (en) 2003-01-31
ID26646A (id) 2001-01-25
DE122006000035I1 (de) 2006-11-23
AU746856B2 (en) 2002-05-02
KR100432276B1 (ko) 2004-05-20
TW579299B (en) 2004-03-11
JP3984785B2 (ja) 2007-10-03
NO20004915L (no) 2000-11-08
EP1033978A1 (fr) 2000-09-13
US10322093B2 (en) 2019-06-18
ES2170573T3 (es) 2002-08-01
IL138722A (en) 2005-11-20
US20080050424A1 (en) 2008-02-28
CN1142773C (zh) 2004-03-24
SK284618B6 (sk) 2005-07-01
PT1033978E (pt) 2002-06-28
DE122006000035I2 (de) 2009-05-20
WO1999049852A1 (fr) 1999-10-07
BR9909313B1 (pt) 2013-11-12
PL343255A1 (en) 2001-07-30
NO2008014I2 (no) 2010-04-19
US20050033065A1 (en) 2005-02-10
HK1031196A1 (en) 2001-06-08
DE59900581D1 (de) 2002-01-31
LU91269I9 (fr) 2018-12-31
DE19814084A1 (de) 1999-10-14
HUP0101519A2 (hu) 2001-09-28
BRPI9909313B8 (pt) 2021-05-25
CA2326630C (fr) 2006-12-05
CZ20003581A3 (en) 2001-05-16
CZ297889B6 (cs) 2007-04-25
US20080138389A1 (en) 2008-06-12
US10251844B2 (en) 2019-04-09
JP2002509878A (ja) 2002-04-02
SK14462000A3 (sk) 2001-04-09
DK1033978T3 (da) 2002-04-15
PL193074B1 (pl) 2007-01-31
KR20010042336A (ko) 2001-05-25
TR200002829T2 (tr) 2001-01-22
ATE210973T1 (de) 2002-01-15
FR06C0025I2 (fr) 2007-05-25
HU226733B1 (en) 2009-08-28
NO20080489L (no) 2000-08-11
DE19814084B4 (de) 2005-12-22
MY119660A (en) 2005-06-30
IL138722A0 (en) 2001-10-31
NO325766B1 (no) 2008-07-14
NO20004915D0 (no) 2000-09-29
AU2934199A (en) 1999-10-18
ZA200005261B (en) 2001-05-22
FR06C0025I1 (fr) 2007-04-27
CN1295470A (zh) 2001-05-16
AR014778A1 (es) 2001-03-28
US6884434B1 (en) 2005-04-26
EP1033978B1 (fr) 2001-12-19
US7413747B2 (en) 2008-08-19
AU746856C (en) 1999-10-18

Similar Documents

Publication Publication Date Title
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
LU91138I2 (fr) Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
FI20020892L (fi) Farmaseuttisesti aktiivisia isoindoliinin derivaattoja
LU91501I2 (fr) Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU91363I2 (fr) Méthoxy polyéthylène glycol-époétine bêta et ses sels pharmaceutiquement acceptables (MIRCERA)
NO20003721D0 (no) Farmasøytisk aktivt morfolinol
NO2008014I2 (no) Rotigotin
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU91849I2 (fr) Cimicoxib et ses dérivés pharmaceutiquement acceptables - CIMALGEX®.
EE200100022A (et) Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon